ALK1 as a novel therapeutic target for CD30⁺ T-anaplastic large cell lymphoma.
Affiliation of authors: Division of Hematology/Oncology, University of Florida, Gainesville, FL (JWH, NHD).
Jack W
JW
Hsu
Nam H
NH
Dang
D030301:Activin Receptors, Type II / Q000187:drug effects* / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D000079963:Brentuximab Vedotin; D000077547:Crizotinib; D018572:Disease-Free Survival; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D017730:Ki-1 Antigen / Q000378:metabolism*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control*; D058990:Molecular Targeted Therapy / Q000379:methods*; D011379:Prognosis; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D055502:Secondary Prevention; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; D000079963:Brentuximab Vedotin; C425364:ACVRL1 protein, human; D030301:Activin Receptors, Type II